0102030405
Industry News
UBT251 vs Retatrutide: The Next Chapter in Triple-Agonist Obesity Research
2026-07-22
The development of obesity medicines is moving rapidly beyond conventional GLP-1 receptor agonists. After single-receptor treatments such as semaglutide and dual GLP-1/GIP agonists such as tirzep...
view
detail
Dual targets lead the metabolic health revolution. Tirzepatide (2023788-19-2) has become the king of drugs, empowering the global pharmaceutical industry to upgrade
2026-03-12
The global field of metabolic disease treatment has witnessed iterative breakthroughs. The GLP-1/GIP dual-target agonist track continues to explode. As a leading product in this field, Tirzepatid...
view
detail